Vivek Subbiah shared a post by Fabrice Andre, Head of Research Division at Gustave Roussy and President-Elect at ESMO on X, adding:

“Such a delight to deliver the keynote at the esteemed PRISM center in Paris, France. Huge thanks to the incredible Fabrice Andre for the invitation.

Prism Center – National Precision Oncology Center – A unique partnership between Gustave Roussy, Centrale Supélec, University of Paris-Saclay, Unicancer, and Inserm.

Paris Precision oncology = Perfect synergy of place, people, and purpose.”

Quoting Fabrice Andre’s post:

“The kick-off Meeting of the Prism Center IHU-A will be on Thursday May 2nd.

It’s an opportunity to organise a nice seminar around Precision Medicine with Vivek Subbiah and Nicholas McGranahan as speakers.

You are welcome to join us (and there is a cocktail at the end!).”

Source: Vivek Subbiah/X and Fabrice Andre/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.